<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372665">
  <stage>Registered</stage>
  <submitdate>29/03/2017</submitdate>
  <approvaldate>31/03/2017</approvaldate>
  <actrnumber>ACTRN12617000473369</actrnumber>
  <trial_identification>
    <studytitle>A clinical trial to evaluate the safety of nivolumab for relapsed or residual haematological cancers after blood or bone marrow transplantation</studytitle>
    <scientifictitle>Pilot study of the tolerability of nivolumab for relapsed or residual haematological malignancies after allogeneic haematopoietic stem cell transplantation</scientifictitle>
    <utrn />
    <trialacronym>NIVALLO</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Haematological malignancies</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Hodgkin's</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single-arm study of nivolumab 3mg/kg intravenously every 2 weeks for up to 48 weeks in an outpatient setting. </interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is the safety of nivolumab post-allogeneic transplant, as measured by the cumulative incidence of acute and chronic graft versus host disease. Established criteria for acute (Glucksberg criteria) and chronic (NIH consensus criteria) will be used to assess the severity of GVHD.</outcome>
      <timepoint>2, 4, 8, 16, 24, 48 weeks after the first dose of nivolumab</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tumour response to nivolumab therapy using various established response criteria specific to the relevant primary haematological malignancy</outcome>
      <timepoint>8, 16, 24, 48 weeks after first dose of nivolumab</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age &gt; 18 years
Prior allogeneic stem cell transplant for a haematological malignancy
Confirmed relapse or persistent haematological malignancy post allogeneic transplant
Immunosuppression cessation for minimum 2 weeks
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Current evidence of any grade of GVHD
Prior history of grade 2 or higher acute GVHD
Moderate chronic GVHD within the previous 6 months or any prior history of severe chronic GVHD
Known autoimmune disease
Positive hepatitis B virus surface antigen
Positive hepatitis C virus antibody
Known HIV infection</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>N/A</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods>Descriptive statistics of response rate using established criteria. Survival analyses using Kaplan-Meier method. Cumulative incidence of acute and chronic GVHD calculated taking into account non-GVHD mortality as a competing risk.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>3/04/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>14</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress>Grattan Street, Parkville, VIC, Australia 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bristol-Myers Squibb</fundingname>
      <fundingaddress>4 Nexus Court, Mulgrave, VIC, Australia 3170</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to evaluate the safety of nivolumab for relapsed or residual haematological cancers after blood or bone marrow transplantation

Who is it for?
You may be eligible to join this study if you are aged 18 years or above and have 
confirmed relapse or persistent haematological malignancy post allogeneic transplant.

Study details
All participants in this study will be administered a drug called nivolumab every 2 weeks for up to 48 weeks. Each time you will receive the same dose (3mg/kg) intravenously (through a vein). Assessments will be carried out throughout the 48 week period to evaluate occurrence of graft versus host disease and to measure tumour response to nivolumab therapy.

Study significance
There is a lack of effective treatment for relapse or persistence of haematological cancer after allogeneic transplant. This study will investigate a promising new approach to treat cancer for these patients, by using the harnessing the immune system to eliminate cancer cells. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Royal Melbourne Hospital
300 Grattan Street
Parkville VIC 3050
Australia</ethicaddress>
      <ethicapprovaldate>10/11/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>David Ritchie</name>
      <address>Royal Melbourne Hospital
300 Grattan Street, Parkville, VIC 3050
Australia</address>
      <phone>+61 3 93422520</phone>
      <fax />
      <email>david.ritchie@mh.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>David Ritchie</name>
      <address>Royal Melbourne Hospital
300 Grattan Street, Parkville, VIC 3050
Australia</address>
      <phone>+61 3 93422520</phone>
      <fax />
      <email>david.ritchie@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>David Ritchie</name>
      <address>Royal Melbourne Hospital
300 Grattan Street, Parkville, VIC 3050
Australia</address>
      <phone>+61 3 93422520</phone>
      <fax />
      <email>david.ritchie@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Eric Wong</name>
      <address>Royal Melbourne Hospital
300 Grattan Street, Parkville, VIC 3050
Australia</address>
      <phone>+61 3 93427000</phone>
      <fax />
      <email>eric.wong@mh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>